ADC Therapeutics reports $20M in revenue with critical clinical readouts imminent

ADC Therapeutics (NYSE:ADCT), a commercial-stage biotechnology company specializing in antibody-drug conjugates (ADCs), reported its financial results for the first quarter of 2026.

The company recorded net product revenue of $20 million, primarily driven by continued market penetration of its lead asset in the oncology space.

The company reported a GAAP net loss of $33 million, or $0.21 per share.

On an adjusted basis, the net loss was $19.7 million ($0.13 per share), reflecting disciplined expense management as the company prioritizes its late-stage clinical pipeline.

As of March 31, 2026, ADC Therapeutics held $231 million in cash and cash equivalents.

Management highlighted that this capital position, combined with projected product revenue and operational efficiencies, provides the company with a financial runway extending at least into 2028.

This long-term stability allows the firm to fully fund its current clinical development programs through multiple high-impact milestones.

The quarter’s report emphasized a heavy upcoming schedule of clinical data readouts that will likely define the company's mid-term growth trajectory.

Topline data from the LOTIS-5 confirmatory trial is expected in the second quarter of 2026.

This trial is critical for cementing the regulatory status and expanding the market reach of the company’s lead therapy.

Meanwhile, full data from both the LOTIS-5 and LOTIS-7 programs are anticipated by the end of 2026.

LOTIS-7, in particular, is being closely watched for its potential to demonstrate the safety and efficacy of combining ADCs with other standard-of-care treatments, potentially moving the company's therapies into earlier lines of treatment for lymphoma and other hematologic malignancies.